TPH1 and 5-HT(7) Receptor Overexpression Leading to Gemcitabine-Resistance Requires Non-Canonical Permissive Action of EZH2 in Pancreatic Ductal Adenocarcinoma

SIMPLE SUMMARY: Most patients with pancreatic cancer initially respond to the first-choice drug gemcitabine, but the cancer cells rapidly acquire drug resistance, resulting in poor survival. In this study, we investigated whether the serotonin (5-hydroxytryptamine, 5-HT) system plays an important ro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaudhary, Prakash, Guragain, Diwakar, Chang, Jae-Hoon, Kim, Jung-Ae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582390/
https://www.ncbi.nlm.nih.gov/pubmed/34771469
http://dx.doi.org/10.3390/cancers13215305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582390/
https://www.ncbi.nlm.nih.gov/pubmed/34771469
http://dx.doi.org/10.3390/cancers13215305

Ejemplares similares